Company · CIK 0001006281 · SIC 2836 — Biological Products, (No Diagnostic Substances) · NYSE
Protalix BioTherapeutics, Inc. · PLX
Insider activity reported against this company. All insider holders · On EDGAR ↗
Reported at this company — common stock
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| May 16, 2017 PForm 4 → | May 16, 9:31 am EDT | Moshe ManorPresident & CEO, Director | 50,000 | $0.81 | $40,500 | 50,000 | — | plan? |
| Dec 2, 2016 SForm 4 → | Dec 6, 3:26 pm EST | Camber Capital Management LLC10% Owner | 2,500,000 | $0.3168 | $792,000 | 10,775,000 | −18.8% | plan? |
| Sep 15, 2016 MForm 4 → | Sep 16, 5:01 pm EDT | Yoseph ShaaltielExecutive VP, R&D | 122,162 | $0.001 | $122 | 585,916 | — | plan? |
| Dec 14, 2015 PForm 4 → | Dec 15, 7:30 am EST | Yossi MaimonVice President & CFO | 10,000 | $0.78 | $7,800 | 10,000 | — | plan? |
| Oct 19, 2015 PForm 4 → | Oct 20, 2:18 pm EDT | Camber Capital Management LLC10% Owner | 4,000,423 | $1.00 | $4,000,436 | 13,275,000 | +43.1% | plan? |
Reported at this company — derivatives (options, RSUs, warrants)
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 3, 2026 AForm 4 → | Sep 9, 5:00 pm EDT | Aharon SchwartzDirector | 25,500 | — | — | 8,500 | — | late |
| Sep 3, 2026 AForm 4 → | Sep 4, 6:00 am EDT | Yaron NaosSr. VP & COO | 168,000 | — | — | 56,000 | — | |
| Sep 3, 2026 AForm 4 → | Sep 4, 6:00 am EDT | Christian ElzeDirector | 25,500 | — | — | 8,500 | — | |
| Sep 3, 2026 AForm 4 → | Sep 4, 6:00 am EDT | Gwen A MelincoffDirector | 25,500 | — | — | 8,500 | — | |
| Sep 3, 2026 AForm 4 → | Sep 4, 6:00 am EDT | Pol F BoudesDirector | 25,500 | — | — | 8,500 | — | |
| Sep 3, 2026 AForm 4 → | Sep 4, 6:00 am EDT | Dror BashanPRESIDENT AND CEO, Director | 480,000 | — | — | 160,000 | — | |
| Sep 3, 2026 AForm 4 → | Sep 4, 6:00 am EDT | Amos Bar-ShalevDirector | 25,500 | — | — | 8,500 | — | |
| Sep 3, 2026 AForm 4 → | Sep 4, 6:00 am EDT | Zvi Shmuel BenDirector | 25,500 | — | — | 8,500 | — | |
| Sep 3, 2026 AForm 4 → | Sep 4, 6:00 am EDT | Eliot ForsterDirector | 25,500 | — | — | 8,500 | — | |
| Sep 13, 2018 AForm 4 → | Sep 14, 4:31 pm EDT | Yossi MaimonVP, Chief Financial Officer | 700,000 | — | — | 700,000 | — | |
| Sep 13, 2018 AForm 4 → | Sep 14, 4:31 pm EDT | Einat Brill AlmonSVP, Product Development | 700,000 | — | — | 700,000 | — | |
| Sep 13, 2018 AForm 4 → | Sep 14, 4:30 pm EDT | Yaron NaosSr. VP, Operations | 600,000 | — | — | 600,000 | — | |
| Sep 13, 2018 AForm 4 → | Sep 14, 4:30 pm EDT | Moshe ManorPresident & CEO, Director | 1,300,000 | — | — | 1,300,000 | — | |
| Sep 13, 2018 AForm 4 → | Sep 14, 4:30 pm EDT | Yoseph ShaaltielExecutive VP, R&D | 700,000 | — | — | 700,000 | — | |
| Sep 15, 2016 MForm 4 → | Sep 16, 5:01 pm EDT | Yoseph ShaaltielExecutive VP, R&D | 122,162 | — | — | 0 | — | |
| Mar 23, 2015 AForm 4 → | May 7, 5:25 pm EDT | Yossi MaimonVP, Chief Financial Officer | 250,000 | — | — | 250,000 | — | late |
| Mar 23, 2015 AForm 4 → | May 7, 5:24 pm EDT | Yoseph ShaaltielExecutive VP, R&D | 275,000 | — | — | 275,000 | — | late |
| Mar 23, 2015 AForm 4 → | May 7, 5:23 pm EDT | Tzvi PalashChief Operating Officer | 125,000 | — | — | 125,000 | — | late |
| Mar 23, 2015 AForm 4 → | May 7, 5:21 pm EDT | Einat Brill AlmonSVP, Product Development | 250,000 | — | — | 250,000 | — | late |